Class II HLA Epitope Matching—A Strategy to Minimize De Novo Donor‐Specific Antibody Development and Improve Outcomes

De novo donor‐specific antibody (dnDSA) develops in 15–25% of renal transplant recipients within 5 years of transplantation and is associated with 40% lower graft survival at 10 years. HLA epitope matching is a novel strategy that may minimize dnDSA development. HLAMatchmaker software was used to characterize epitope mismatches at 395 potential HLA‐DR/DQ/DP conformational epitopes for 286 donor–recipient pairs. Epitope specificities were assigned using single antigen HLA bead analysis and correlated with known monoclonal alloantibody epitope targets. Locus‐specific epitope mismatches were more numerous in patients who developed HLA‐DR dnDSA alone (21.4 vs. 13.2, p < 0.02) or HLA‐DQ dnDSA alone (27.5 vs. 17.3, p < 0.001). An optimal threshold for epitope mismatches (10 for HLA‐DR, 17 for HLA‐DQ) was defined that was associated with minimal development of Class II dnDSA. Applying these thresholds, zero and 2.7% of patients developed dnDSA against HLA‐DR and HLA‐DQ, respectively, after a median of 6.9 years. Epitope specificity analysis revealed that 3 HLA‐DR and 3 HLA‐DQ epitopes were independent multivariate predictors of Class II dnDSA. HLA‐DR and DQ epitope matching outperforms traditional low‐resolution antigen‐based matching and has the potential to minimize the risk of de novo Class II DSA development, thereby improving long‐term graft outcome.

[1]  Ulrich Mansmann,et al.  A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants , 2003, Transplantation.

[2]  N. Sinha,et al.  Differences in electrostatic properties at antibody-antigen binding sites: implications for specificity and cross-reactivity. , 2002, Biophysical journal.

[3]  W. Suki,et al.  Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. , 2012, Kidney international.

[4]  James Robinson,et al.  The IMGT/HLA database , 2008, Nucleic Acids Res..

[5]  P. Terasaki,et al.  Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. , 2005, Journal of the American Society of Nephrology : JASN.

[6]  J. Ringers,et al.  Simpler and Equitable Allocation of Kidneys From Postmortem Donors Primarily Based on Full HLA-DR Compatibility , 2007, Transplantation.

[7]  P. Halloran,et al.  De Novo Donor‐Specific Antibody at the Time of Kidney Transplant Biopsy Associates with Microvascular Pathology and Late Graft Failure , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  Junchao Cai,et al.  Epitopes of the HLA-A, B, C, DR, DQ and MICA antigens. , 2007, Clinical transplants.

[9]  Nadim El-Awar,et al.  HLA class II DQ epitopes. , 2006, Clinical transplants.

[10]  G. Iaria,et al.  Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: results of sixteen-year monitoring by flow cytometry. , 2006, Clinical transplants.

[11]  P. Terasaki,et al.  Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens. , 2009, Clinical transplants.

[12]  C. Legendre,et al.  Antibody‐Mediated Microcirculation Injury Is the Major Cause of Late Kidney Transplant Failure , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  G. Ghiggeri,et al.  Posttransplant De Novo Donor‐Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody‐Mediated Rejection , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  L. Sharples,et al.  Predicting HLA Class I Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms , 2009, Transplantation.

[15]  A. Zeevi,et al.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. , 2008, Transplant immunology.

[16]  P. Nickerson,et al.  Evolution and Clinical Pathologic Correlations of De Novo Donor‐Specific HLA Antibody Post Kidney Transplant , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  J. Sellarésa,et al.  Understanding the Causes of Kidney Transplant Failure : The Dominant Role of Antibody-Mediated Rejection and Nonadherence , 2011 .

[18]  R. Duquesnoy,et al.  Correlations between Terasaki's HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens. , 2009, Tissue antigens.

[19]  P. Terasaki,et al.  HLA class II DQA and DQB epitopes: recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines. , 2013, Human immunology.

[20]  M. Stegall,et al.  Identifying Specific Causes of Kidney Allograft Loss , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  R. Duquesnoy,et al.  Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens. , 2009, Tissue antigens.

[22]  A. Matas,et al.  Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  L. Sharples,et al.  Predicting HLA Class II Alloantigen Immunogenicity From the Number and Physiochemical Properties of Amino Acid Polymorphisms , 2011, Transplantation.

[24]  D. Roelen,et al.  THE NUMBER OF AMINO ACID TRIPLET DIFFERENCES BETWEEN PATIENT AND DONOR IS PREDICTIVE FOR THE ANTIBODY REACTIVITY AGAINST MISMATCHED HUMAN LEUKOCYTE ANTIGENS1 , 2004, Transplantation.

[25]  L. Thacker,et al.  Human leukocyte antigens DR and AB and kidney retransplantation , 2003, Transplantation.

[26]  J. Bradley,et al.  High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. , 2011, Human immunology.

[27]  P. Archdeacon,et al.  Summary of FDA Antibody‐Mediated Rejection Workshop , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  C. Roufosse,et al.  De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy , 2012, Transplantation.

[29]  Rene J Duquesnoy,et al.  A structurally based approach to determine HLA compatibility at the humoral immune level. , 2006, Human immunology.

[30]  E. Thorsby,et al.  A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes: a single-center study of first cadaveric kidneys to nonsensitized recipients. , 1998, Transplantation.

[31]  J. Boletis,et al.  Long‐term follow up for anti‐HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[32]  P. Nickerson,et al.  Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation , 2013, Current opinion in organ transplantation.